In conclusion, our analysis of 8526 patients, as the largest data set reported so far to our best knowledge from randomized trials with consistent central and genomic assessment and survival results, does not support the concept that HER2-low is a distinct BC subtype. This evidence concerns the gene ERBB2 and breast cancer.